Angelica Lindén Hirschberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/708877/publications.pdf

Version: 2024-02-01

147 papers 8,059 citations

46 h-index 83 g-index

149 all docs 149 docs citations

149 times ranked 7849 citing authors

#	Article	IF	Citations
1	Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e475-e486.	1.8	17
2	Analysis of Neurodevelopmental Disorders in Offspring of Mothers With Eating Disorders in Sweden. JAMA Network Open, 2022, 5, e2143947.	2.8	15
3	Challenging Aspects of Research on the Influence of the Menstrual Cycle and Oral Contraceptives on Physical Performance. Sports Medicine, 2022, 52, 1453-1456.	3.1	12
4	The impact of adherence and therapy regimens on quality of life in patients with congenital adrenal hyperplasia. Clinical Endocrinology, 2022, 96, 666-679.	1.2	5
5	Sexual Function in Women with Differences of Sex Development or Premature Loss of Gonadal Function. Journal of Sexual Medicine, 2022, 19, 249-256.	0.3	1
6	The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement. Maturitas, 2022, 158, 70-77.	1.0	24
7	Molecular Regulators of Muscle Mass and Mitochondrial Remodeling Are Not Influenced by Testosterone Administration in Young Women. Frontiers in Endocrinology, 2022, 13, 874748.	1.5	3
8	Klotho Polymorphism in Association With Serum Testosterone and Knee Strength in Women After Testosterone Administration. Frontiers in Physiology, 2022, 13, .	1.3	4
9	Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Maturitas, 2022, 163, 1-14.	1.0	33
10	Reproductive and Perinatal Outcomes in Women with Congenital Adrenal Hyperplasia: A Population-based Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e957-e965.	1.8	27
11	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. Maturitas, 2021, 143, 223-230.	1.0	27
12	Disposition of Urinary and Serum Steroid Metabolites in Response to Testosterone Administration in Healthy Women. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 697-707.	1.8	23
13	Higher blood pressure in normal weight women with PCOS compared to controls. Endocrine Connections, 2021, 10, 154-163.	0.8	13
14	Posterior compartment symptoms in primiparous women 1 year after non-assisted vaginal deliveries: a Swedish cohort study. International Urogynecology Journal, 2021, 32, 1825-1832.	0.7	5
15	Treatment with assisted reproduction technologies in women with acute hepatic porphyria. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 1712-1721.	1.3	3
16	Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. Maturitas, 2021, 148, 55-61.	1.0	35
17	Urinary Steroid Profile in Elite Female Athletes in Relation to Serum Androgens and in Comparison With Untrained Controls. Frontiers in Physiology, 2021, 12, 702305.	1.3	9
18	Interaction between insulin and androgen signalling in decidualization, cell migration and trophoblast invasion <i>in vitro</i> . Journal of Cellular and Molecular Medicine, 2021, 25, 9523-9532.	1.6	8

#	Article	IF	Citations
19	IGF-I and IGFBP-1 in Relation to Body Composition and Physical Performance in Female Olympic Athletes. Frontiers in Endocrinology, 2021, 12, 708421.	1.5	3
20	Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement. Maturitas, 2021, 151, 55-62.	1.0	28
21	A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology, 2021, 133, 105426.	1.3	26
22	Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2063-e2077.	1.8	38
23	Female Hyperandrogenism in Elite Sports and the Athletic Triad. Seminars in Reproductive Medicine, 2021, , .	0.5	1
24	Association between prolactin receptor expression and proliferation in the endometrium of obese women with polycystic ovary syndrome. Gynecological Endocrinology, 2020, 36, 226-232.	0.7	13
25	Women with polycystic ovary syndrome present with altered endometrial expression of stanniocalcin-1â€. Biology of Reproduction, 2020, 102, 306-315.	1.2	15
26	Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas, 2020, 131, 91-101.	1.0	37
27	Association of Maternal Eating Disorders With Pregnancy and Neonatal Outcomes. JAMA Psychiatry, 2020, 77, 285.	6.0	41
28	The Mediterranean diet and menopausal health: An EMAS position statement. Maturitas, 2020, 139, 90-97.	1.0	39
29	Insulin regulation of solute carrier family 2 member 1 (glucose transporter 1) expression and glucose uptake in decidualizing human endometrial stromal cells: an in vitro study. Reproductive Biology and Endocrinology, 2020, 18, 117.	1.4	4
30	OR25-02 A Phase 3 Study of a Modified-Release Hydrocortisone in the Treatment of Congenital Adrenal Hyperplasia. Journal of the Endocrine Society, 2020, 4, .	0.1	1
31	Enhanced Skeletal Muscle Oxidative Capacity and Capillary-to-Fiber Ratio Following Moderately Increased Testosterone Exposure in Young Healthy Women. Frontiers in Physiology, 2020, 11, 585490.	1.3	10
32	Digit Ratio (2D:4D) and Physical Performance in Female Olympic Athletes. Frontiers in Endocrinology, 2020, 11, 292.	1.5	18
33	Evidence summaries and recommendations from the international evidenceâ€based guideline for the assessment and management of polycystic ovary syndrome: Lifestyle management. Obesity Reviews, 2020, 21, e13046.	3.1	41
34	A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. Oncologist, 2020, 25, e1846-e1854.	1.9	13
35	Endometrial expression of anti-Mýllerian hormone and its type II receptor in women with polycystic ovary syndrome. Reproductive BioMedicine Online, 2020, 41, 128-137.	1.1	5
36	Fiber type-specific hypertrophy and increased capillarization in skeletal muscle following testosterone administration in young women. Journal of Applied Physiology, 2020, 128, 1240-1250.	1.2	23

#	Article	IF	CITATIONS
37	Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas, 2020, 135, 82-88.	1.0	51
38	Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. Menopause, 2020, 27, 526-534.	0.8	25
39	The role of testosterone in menopausal hormone treatment. What is the evidence?. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 966-969.	1.3	7
40	Dihydrotestosterone potentiates insulin to upâ€regulate prokineticinâ€1 in decidualizing human endometrial stromal cells. Journal of Cellular and Molecular Medicine, 2020, 24, 3242-3245.	1.6	11
41	Effects of moderately increased testosterone concentration on physical performance in young women: a double blind, randomised, placebo controlled study. British Journal of Sports Medicine, 2020, 54, 599-604.	3.1	60
42	Editorial: Exercise and Sport: Their Influences on Women's Health Across the Lifespan. Frontiers in Physiology, 2020, 11, 615468.	1.3	0
43	Female hyperandrogenism and elite sport. Endocrine Connections, 2020, 9, R81-R92.	0.8	30
44	Psychological well-being and personality in relation to weight loss following behavioral modification intervention in obese women with polycystic ovary syndrome: a randomized controlled trial. European Journal of Endocrinology, 2020, 183, 1-11.	1.9	30
45	The digit ratio (2D:4D) and economic preferences: no robust associations in a sample of 330 women. Journal of the Economic Science Association, 2019, 5, 149-169.	1.8	15
46	Changes in premenstrual symptoms in women starting or discontinuing use of oral contraceptives. Gynecological Endocrinology, 2019, 35, 422-426.	0.7	5
47	Mice exposed to maternal androgen excess and diet-induced obesity have altered phosphorylation of catechol-O-methyltransferase in the placenta and fetal liver. International Journal of Obesity, 2019, 43, 2176-2188.	1.6	16
48	Increased Risk of Autoimmune Disorders in 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. Journal of the Endocrine Society, 2019, 3, 1039-1052.	0.1	8
49	Impact of hormonal contraceptives on urinary steroid profile in relation to serum hormone changes and CYP17A1 polymorphism. Drug Testing and Analysis, 2019, 11, 1284-1289.	1.6	13
50	Exercise Recommendations for Women with Polycystic Ovary Syndrome: Is the Evidence Enough?. Sports Medicine, 2019, 49, 1143-1157.	3.1	36
51	Effects of drospirenone and norethisterone acetate combined with estradiol on mammographic density and proliferation of breast epithelial cells—A prospective randomized trial. Maturitas, 2019, 126, 18-24.	1.0	9
52	Sexuality in Adults with Differences/Disorders of Sex Development (DSD): Findings from the dsd-LIFE Study. Journal of Sex and Marital Therapy, 2019, 45, 688-705.	1.0	23
53	Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 256-266.	5.5	106
54	Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention—A randomized controlled trial. Clinical Endocrinology, 2019, 90, 468-478.	1.2	23

#	Article	IF	Citations
55	Hyperandrogenism in Female Athletes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 503-505.	1.8	11
56	Sport and Menses. , 2019, , 461-470.		2
57	Maternal transfer of anti HPV 6 and 11 antibodies upon immunization with the 9-valent HPV vaccine. Human Vaccines and Immunotherapeutics, 2019, 15, 141-145.	1.4	5
58	MON-217 Maternal Androgen Excess and Obesity Induce Cardiac Hypertrophy and Left Ventricular Dysfunction in Female Offspring. Journal of the Endocrine Society, 2019, 3, .	0.1	0
59	Pregnancy greatly affects the steroidal module of the Athlete Biological Passport. Drug Testing and Analysis, 2018, 10, 1070-1075.	1.6	12
60	Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial. Management Science, 2018, 64, 4515-4532.	2.4	19
61	Prokineticin 1 is upâ€regulated by insulin in decidualizing human endometrial stromal cells. Journal of Cellular and Molecular Medicine, 2018, 22, 163-172.	1.6	19
62	Letter to the editor: Sex and the eye test. Psychoneuroendocrinology, 2018, 98, 242-243.	1.3	0
63	Impact of Human Cytomegalovirus Infection and its Immune Response on Survival of Patients with Ovarian Cancer. Translational Oncology, 2018, 11, 1292-1300.	1.7	28
64	Maternal androgen excess and obesity induce sexually dimorphic anxietyâ€like behavior in the offspring. FASEB Journal, 2018, 32, 4158-4171.	0.2	37
65	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 2018, 110, 364-379.	0.5	759
66	Serum androgen levels are positively correlated with athletic performance and competition results in elite female athletes. British Journal of Sports Medicine, 2018, 52, 1531-1532.	3.1	38
67	Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndromeâ€â€¡. Human Reproduction, 2018, 33, 1602-1618.	0.4	1,015
68	Cognitive abilities in women with complete androgen insensitivity syndrome and women with gonadal dysgenesis. Psychoneuroendocrinology, 2018, 98, 233-241.	1.3	3
69	Role of testosterone and Y chromosome genes for the masculinization of the human brain. Human Brain Mapping, 2017, 38, 1801-1814.	1.9	47
70	Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertility and Sterility, 2017, 107, 788-795.e2.	0.5	81
71	Treatment of premenstrual dysphoric disorder with the GABA A receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial. Psychoneuroendocrinology, 2017, 80, 46-55.	1.3	93
72	Effect of age on serum prostate-specific antigen in women. Clinical Chemistry and Laboratory Medicine, 2017, 55, e271-e272.	1.4	3

#	Article	IF	Citations
73	A first-choice combined oral contraceptive influences general well-being in healthy women: a double-blind, randomized, placebo-controlled trial. Fertility and Sterility, 2017, 107, 1238-1245.	0.5	57
74	Progesterone Receptors and Proliferation of the Endometrium in Obese Women With Polycystic Ovary Syndrome—A Lifestyle Intervention Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1244-1253.	1.8	15
75	The prevalence of Type 2 diabetes is not increased in normal-weight women with PCOS. Human Reproduction, 2017, 32, 2279-2286.	0.4	40
76	Fertility outcome and information on fertility issues in individuals with different forms of disorders of sex development: findings from the dsd-LIFE study. Fertility and Sterility, 2017, 108, 822-831.	0.5	55
77	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet, The, 2017, 390, 2143-2159.	6.3	314
78	In Reply:. Menopause, 2017, 24, 232-233.	0.8	0
79	Increased psychiatric morbidity in women with complete androgen insensitivity syndrome or complete gonadal dysgenesis. Journal of Psychosomatic Research, 2017, 101, 122-127.	1.2	22
80	Serum androgen profile and physical performance in women Olympic athletes. British Journal of Sports Medicine, 2017, 51, 1301-1308.	3.1	57
81	Are carriers of (i) CYP21A2 (i) mutations less vulnerable to psychological stress? A population-based national cohort study. Clinical Endocrinology, 2017, 86, 317-324.	1.2	8
82	Reduced Frequency of Biological and Increased Frequency of Adopted Children in Males With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4191-4199.	1.8	50
83	SERUM ANDROGEN PROFILE, BODY COMPOSITION AND PHYSICAL PERFORMANCE IN FEMALE OLYMPIC ATHLETES. British Journal of Sports Medicine, 2017, 51, 296.1-296.	3.1	0
84	Serum complexed and free prostate specific antigen levels are lower in female elite athletes in comparison to control women. F1000Research, 2017, 6, 1131.	0.8	7
85	Dysregulation of In Vitro Decidualization of Human Endometrial Stromal Cells by Insulin via Transcriptional Inhibition of Forkhead Box Protein O1. PLoS ONE, 2017, 12, e0171004.	1.1	38
86	Should we individualize lipid profiling in women with polycystic ovary syndrome?. Human Reproduction, 2016, 31, 2791-2795.	0.4	9
87	Combined Oral Contraceptives and Sexual Function in Women—a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4046-4053.	1.8	45
88	Risk of venous thromboembolism associated with local and systemic use of hormone therapy in periand postmenopausal women and in relation to type and route of administration. Menopause, 2016, 23, 593-599.	0.8	64
89	Endometrial Expression of Estrogen Receptors and the Androgen Receptor in Women With Polycystic Ovary Syndrome: A Lifestyle Intervention Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 561-571.	1.8	33
90	Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study. Journal of Sexual Medicine, 2016, 13, 413-424.	0.3	14

#	Article	IF	Citations
91	Lost workdays in uterine cervical cancer survivors compared to the general population: impact of treatment and relapse. Journal of Cancer Survivorship, 2016, 10, 514-523.	1.5	8
92	"lt's Part of Me, Not All of Me― Young Women's Experiences of Receiving a Diagnosis Related to Diverse Sex Development. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 338-343.	0.3	25
93	Biomarkers of nutrition and stress in pregnant women with a history of eating disorders in relation to head circumference and neurocognitive function of the offspring. BMC Pregnancy and Childbirth, 2015, 15, 318.	0.9	16
94	Hormone therapy after uterine cervical cancer treatment. Menopause, 2015, 22, 633-639.	0.8	19
95	Congenital Adrenal Hyperplasia, Polycystic Ovary Syndrome and criminal behavior: A Swedish population based study. Psychiatry Research, 2015, 229, 953-959.	1.7	12
96	Identification and prediction of the fertile window using NaturalCycles. European Journal of Contraception and Reproductive Health Care, 2015, 20, 403-408.	0.6	62
97	Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study. Psychoneuroendocrinology, 2015, 60, 195-205.	1.3	96
98	Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3520-3528.	1.8	153
99	Sex hormone levels as determinants of bone mineral density and osteoporosis in Vietnamese women and men. Journal of Bone and Mineral Metabolism, 2015, 33, 658-665.	1.3	21
100	Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women – a PET study. NeuroImage, 2015, 106, 47-54.	2.1	33
101	The Impact of Genetics and Hormonal Contraceptives on the Steroid Profile in Female Athletes. Frontiers in Endocrinology, 2014, 5, 50.	1.5	24
102	Increased Mortality in Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2715-E2721.	1.8	138
103	Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas, 2014, 77, 32-36.	1.0	7 5
104	Serum Androgen Levels in Elite Female Athletes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4328-4335.	1.8	84
105	Serum antimÃ $\frac{1}{4}$ llerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Fertility and Sterility, 2013, 100, 1096-1102.	0.5	60
106	Cognitive function in association with sex hormones in postmenopausal women. Gynecological Endocrinology, 2013, 29, 59-62.	0.7	60
107	Are the New Policies on Hyperandrogenism in Elite Female Athletes Really Out of Bounds? Response to "Out of Bounds? A Critique of the New Policies on Hyperandrogenism in Elite Female Athletes― American Journal of Bioethics, 2013, 13, 63-65.	0.5	27
108	Oral Contraceptives Do Not Affect Muscle Strength and Hop Performance in Active Women. Clinical Journal of Sport Medicine, 2013, 23, 202-207.	0.9	27

#	Article	IF	Citations
109	Body Composition and Endocrine Profile of Male Olympic Athletes Striving for Leanness. Clinical Journal of Sport Medicine, 2013, 23, 197-201.	0.9	41
110	Estrogen Supports Urothelial Defense Mechanisms. Science Translational Medicine, 2013, 5, 190ra80.	5.8	109
111	Sex hormones, appetite and eating behaviour in women. Maturitas, 2012, 71, 248-256.	1.0	200
112	The Influence of Menstrual Phases on Pain Modulation in Healthy Women. Journal of Pain, 2012, 13, 646-655.	0.7	80
113	A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and Sterility, 2011, 95, 152-157.	0.5	41
114	Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertility and Sterility, 2011, 96, 1508-1513.	0.5	110
115	A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause, 2010, 17, 72-79.	0.8	27
116	Polycystic Ovary Syndrome, Obesity and Reproductive Implications. Women's Health, 2009, 5, 529-542.	0.7	54
117	The Effect of Transdermal Testosterone on Mammographic Density in Postmenopausal Women Not Receiving Systemic Estrogen Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4907-4913.	1.8	36
118	A randomized trial of the effect of estrogen and testosterone on economic behavior. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6535-6538.	3.3	164
119	Hyperandrogenism May Explain Reproductive Dysfunction in Olympic Athletes. Medicine and Science in Sports and Exercise, 2009, 41, 1241-1248.	0.2	95
120	Early maternal adjustment in women with eating disorders. International Journal of Eating Disorders, 2008, 41, 405-410.	2.1	55
121	Prospective followâ€up of menstrual disorders in adolescence and prognostic factors. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 1162-1168.	1.3	69
122	Key lipogenic gene expression can be decreased by estrogen in human adipose tissue. Fertility and Sterility, 2008, 90, 44-48.	0.5	82
123	Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. New England Journal of Medicine, 2008, 359, 2005-2017.	13.9	427
124	Special Attention to the Weight-Control Strategies Employed by Olympic Athletes Striving for Leanness Is Required. Clinical Journal of Sport Medicine, 2008, 18, 5-9.	0.9	40
125	Effects of Testosterone Treatment on Endometrial Proliferation in Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2169-2175.	1.8	51
126	An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause, 2007, 14, 89-96.	0.8	46

#	Article	IF	CITATIONS
127	Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause, 2007, 14, 183-190.	0.8	99
128	Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertility and Sterility, 2007, 88, 100-106.	0.5	38
129	Plasma ghrelin and gastric pacing in morbidly obese patients. Metabolism: Clinical and Experimental, 2007, 56, 1017-1021.	1.5	14
130	Menstrual disorders and associated factors among adolescent girls visiting a youth clinic. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 65-72.	1.3	47
131	Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertility and Sterility, 2006, 86, 136-144.	0.5	62
132	Knee joint kinaesthesia and neuromuscular coordination during three phases of the menstrual cycle in moderately active women. Knee Surgery, Sports Traumatology, Arthroscopy, 2006, 14, 383-389.	2.3	29
133	Bone mineral density in bulimic women – influence of endocrine factors and previous anorexia. European Journal of Endocrinology, 2006, 155, 245-251.	1.9	55
134	Polycystic ovary syndrome in bulimic women – an evaluation based on the new diagnostic criteria. Gynecological Endocrinology, 2006, 22, 388-394.	0.7	49
135	Pregnancy and Neonatal Outcomes in Women With Eating Disorders. Obstetrics and Gynecology, 2005, 105, 255-260.	1.2	184
136	Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. American Journal of Obstetrics and Gynecology, 2005, 193, 352-360.	0.7	58
137	Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clinical Endocrinology, 2005, 63, 450-455.	1.2	49
138	Altered Postural Control during the Luteal Phase in Women with Premenstrual Symptoms. Neuroendocrinology, 2005, 81, 150-157.	1.2	32
139	Oral Contraceptives Improve Endothelial Function in Amenorrheic Athletes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3162-3167.	1.8	64
140	Amenorrhea in Female Athletes Is Associated with Endothelial Dysfunction and Unfavorable Lipid Profile. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1354-1359.	1.8	151
141	Diurnal Profiles of Testosterone and Pituitary Hormones Suggest Different Mechanisms for Menstrual Disturbances in Endurance Athletes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 702-707.	1.8	75
142	Effects of Oral Contraceptives on Body Composition and Physical Performance in Female Athletes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4364-4370.	1.8	103
143	Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. Fertility and Sterility, 2003, 79, 947-955.	0.5	98
144	Muscle Strength and Endurance Do Not Significantly Vary Across 3 Phases of the Menstrual Cycle in Moderately Active Premenopausal Women. Clinical Journal of Sport Medicine, 2003, 13, 238-241.	0.9	69

#	Article	IF	CITATIONS
145	Altered adrenal steroid metabolism underlying hypercortisolism in female endurance athletes. Fertility and Sterility, 1995, 63, 1190-1194.	0.5	24
146	The Digit Ratio (2D:4D) and Economic Preferences: No Robust Associations in a Sample of 330 Women. SSRN Electronic Journal, $0,$	0.4	1
147	Female hyperandrogenism and elite sport. Endocrine Abstracts, 0, , .	0.0	O